Terms: = Breast cancer AND ACSL3, PRO2194, 2181, ENSG00000123983, O95573, FACL3, ACS3 AND Prognosis
5 results:
1. Overall survival and associated factors in women with metastatic breast cancer treated with trastuzumab at a public referral institution.
Gonçalves DS; Santos AMRD; Costa SCVD; Costa RSD; Senna KMSE; Zimmermann IR
Rev Bras Epidemiol; 2023; 26():e230045. PubMed ID: 37878833
[TBL] [Abstract] [Full Text] [Related]
2. ACSL family: The regulatory mechanisms and therapeutic implications in cancer.
Quan J; Bode AM; Luo X
Eur J Pharmacol; 2021 Oct; 909():174397. PubMed ID: 34332918
[TBL] [Abstract] [Full Text] [Related]
3. Association of long-chain acyl-coenzyme A synthetase 5 expression in human breast cancer by estrogen receptor status and its clinical significance.
Yen MC; Kan JY; Hsieh CJ; Kuo PL; Hou MF; Hsu YL
Oncol Rep; 2017 Jun; 37(6):3253-3260. PubMed ID: 28498416
[TBL] [Abstract] [Full Text] [Related]
4. Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in cancer.
Chen WC; Wang CY; Hung YH; Weng TY; Yen MC; Lai MD
PLoS One; 2016; 11(5):e0155660. PubMed ID: 27171439
[TBL] [Abstract] [Full Text] [Related]
5. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.
Falkson G; Gelman R; Falkson CI; Glick J; Harris J
J Clin Oncol; 1991 Dec; 9(12):2153-61. PubMed ID: 1960558
[TBL] [Abstract] [Full Text] [Related]
